AZT for children

November 1991
New Scientist;11/2/91, Vol. 132 Issue 1793, p16
Reports that the AIDS drug zidovudine, more commonly known as AZT has been licensed for use in children with HIV in Great Britain.


Related Articles

  • June HIV conference call to focus on prevention of perinatal transmission.  // Public Health Reports;Mar/Apr95, Vol. 110 Issue 2, p232 

    Focuses on the 11th HIV Clinical Conference Call which is scheduled for June 8, 1995. The number of people worldwide who are expected to listen in on the call; Dissemination of information about the clinical implications of administering zidovudine to pregnant women infected with HIV.

  • Disease Progression and Early Viral Dynamics in Human Immunodefiency... Kuhn, Louise; Abrams, Elaine J.; Weedon, Jeremy; Lambert, Genevieve; Schoenbaum, Ellie E.; Nesheim, Steve R.; Palumbo, Paul; Vink, Peter E.; Bultreys, Marc // Journal of Infectious Diseases;7/1/2000, Vol. 182 Issue 1, p104 

    Compares the clinical progression among HIV-infected children born from 1986 to 1997 and exposed or unexposed to zidovudine during prenatal and perinatal periods. Relation between severity of maternal disease and child clinical outcomes; Viral dynamics in first three months of life;...

  • Quality-of-Life Evaluation in a Clinical Trial of Zidovudine Therapy in Patients with Mildly Symptomatic HIV Infection. Gelher, Richard D.; Lenderking, William R.; Cotton, Deborah J.; Cole, Bernard F.; Fischl, Margaret A.; Goldhirsch, Aron; Testa, Marcia A. // Annals of Internal Medicine;6/15/92 Part 1, Vol. 116 Issue 12, p961 

    Presents a study which evaluated the effects of zidovudine therapy in patients with mildly symptomatic HIV infection. Background on HIV infection; Clinical characteristics of the patients; Data and methods used; Results and conclusions.

  • Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection. Collier, Ann C.; Coombs, Robert W.; Fischl, Margaret A.; Skolnik, Paul R.; Northfelt, Donald; Boutin, Paul; Hooper, Carol J.; Kaplan, Lawrence D.; Volberding, Paul A.; Davis, L. Gray; Henrard, Denis R.; Weiler, Stephen; Corey, Lawrence // Annals of Internal Medicine;10/15/93, Vol. 119 Issue 8, p786 

    Presents a study which assessed the safety, pharmacokinetics, and in-vivo virologic activity of the different combination regimens of zidovudine and didanosine compared with zidovudine alone in patients with HIV-1 infection. Toxicity of the study medication; Methods used; Results and discussion.

  • AZT Suggested For Seronegatives.  // Advocate;11/10/87, Issue 485, p45 

    Reports that people at high risk for HIV infection should be given an antiviral like AZT to prevent infection in the United States. Effectiveness of such chemotherapy; Proposed AIDS vaccine; Protection against HIV infection.

  • Zidovudine after occupational exposure to HIV. Jeffries, D.J. // BMJ: British Medical Journal (International Edition);6/8/91, Vol. 302 Issue 6789, p1349 

    Reports the recommendation of zidovudine for chemoprophylaxis after HIV exposure in Great Britain. Emphasis on the clinical and hematological assessment to monitor toxicity; Reservation of zidovudine for health workers exposed to HIV infection; Concerns on the reduction of the risk of transmission.

  • Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500... Montaner, Julio S.G.; Schechter, Martin T. // Annals of Internal Medicine;10/15/95, Vol. 123 Issue 8, p561 

    Compares the safety and efficacy of didanosine with that of continued zidovudine therapy in HIV-infected persons with CD4 cells/mm3. Baseline characteristics; Clinical events; CD4 counts; Viral sensitivity studies; Longitudinal analysis; Adverse events.

  • CLEAN AND SOBER.  // Advocate;6/28/94, Issue 658, p57 

    Reports on the effects of ethanol, marijuana and tobacco use in patients on AZT monotherapy, AZT-ddC combination therapy and ddl monotherapy. Increase in amylase levels.

  • If you're positive, take AZT.  // Joe Weider's Muscle & Fitness;May95, Vol. 56 Issue 5, p48 

    Reports that AZT drug therapy can reduce the risk for mother-to-child HIV transmission. Legal and ethical concerns of AZT drug therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics